GlobeNewswire: Zogenix, Inc Contains the last 10 of 82 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:41:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/03/04/2397124/0/en/Zogenix-To-Present-New-Long-term-Data-on-FINTEPLA-fenfluramine-in-Lennox-Gastaut-Syndrome-LGS-at-AAN-2022.html?f=22&fvtc=4&fvtv=55926Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 20222022-03-04T13:00:00Z<![CDATA[EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company’s research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).]]>https://www.globenewswire.com/news-release/2022/02/28/2393133/0/en/Zogenix-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html?f=22&fvtc=4&fvtv=55926Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results2022-02-28T13:00:00Z<![CDATA[EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.]]>https://www.globenewswire.com/news-release/2022/02/15/2385181/0/en/Zogenix-Supports-New-No-Cost-Genetic-Testing-Program-with-United-Mitochondrial-Disease-Foundation-to-Improve-Diagnosis-of-Mitochondrial-Diseases.html?f=22&fvtc=4&fvtv=55926Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases2022-02-15T13:00:00Z<![CDATA[EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the company is sponsoring a new no-cost genetic testing program, the United Mitochondrial Disease Foundation (UMDF) Pilot Genetic Testing Project, in partnership with UMDF and Probably Genetic, to help patients obtain a confirmed genetic diagnosis of mitochondrial disease. The program is available to any eligible patient in the U.S. with a suspected diagnosis of mitochondrial disease. Mitochondrial diseases are a group of rare, debilitating conditions that can severely impact daily living and quality of life, and are often fatal.5,6]]>https://www.globenewswire.com/news-release/2021/12/21/2356048/0/en/Zogenix-Submits-New-Drug-Application-for-FINTEPLA-Fenfluramine-in-Japan-for-the-Treatment-of-Epileptic-Seizures-Associated-with-Dravet-Syndrome.html?f=22&fvtc=4&fvtv=55926Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome2021-12-21T13:00:00Z<![CDATA[EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA® (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome in Japan. FINTEPLA received Orphan Drug Designation from Japan’s Ministry of Health, Labour & Welfare (MHLW) in August 2021.]]>https://www.globenewswire.com/news-release/2021/12/20/2355192/0/en/Zogenix-Submits-Type-II-Variation-Application-to-the-European-Medicines-Agency-EMA-to-Expand-the-Use-of-FINTEPLA-Fenfluramine-for-the-Treatment-of-Seizures-Associated-with-Lennox-G.html?f=22&fvtc=4&fvtv=55926Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome2021-12-20T13:00:00Z<![CDATA[EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA) for FINTEPLA® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a highly treatment-resistant form of childhood-onset epilepsy. If approved, the application would expand the use of FINTEPLA in Europe beyond Dravet syndrome to include LGS.]]>https://www.globenewswire.com/news-release/2021/12/16/2354076/0/en/Zogenix-Reports-Granting-of-Inducement-Awards.html?f=22&fvtc=4&fvtv=55926Zogenix Reports Granting of Inducement Awards2021-12-16T21:05:00Z<![CDATA[EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to nine (9) new non-executive employees. The awards were made on December 15, 2021, under Zogenix’s 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the company’s board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix as an inducement to join the company. The awards consist of options to purchase an aggregate of 84,400 shares of Zogenix common stock and 17,300 restricted stock units. The options have a ten year term and an exercise price equal to $13.32 the closing price per share of the common stock on the grant date, and vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The restricted stock units vest over a four-year period in four equal annual installments beginning on the first anniversary of the vesting commencement date.]]>https://www.globenewswire.com/news-release/2021/12/02/2345464/0/en/Zogenix-To-Present-New-FINTEPLA-fenfluramine-Data-at-AES-2021.html?f=22&fvtc=4&fvtv=55926Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 20212021-12-02T21:16:34Z<![CDATA[Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome]]>https://www.globenewswire.com/news-release/2021/12/01/2344064/0/en/Zogenix-Announces-U-S-FDA-Acceptance-for-Priority-Review-of-Supplemental-New-Drug-Application-for-FINTEPLA-Fenfluramine-for-the-Treatment-of-Seizures-Associated-with-Lennox-Gastaut.html?f=22&fvtc=4&fvtv=55926Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)2021-12-01T13:00:00Z<![CDATA[Prescription Drug User Fee Act (PDUFA) Target Action Date of March 25, 2022 Prescription Drug User Fee Act (PDUFA) Target Action Date of March 25, 2022]]>https://www.globenewswire.com/news-release/2021/11/17/2336802/0/en/Zogenix-Reports-Granting-of-Inducement-Awards.html?f=22&fvtc=4&fvtv=55926Zogenix Reports Granting of Inducement Awards2021-11-17T21:05:00Z<![CDATA[EMERYVILLE, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to thirteen (13) new non-executive employees. The awards were made on November 15, 2021, under Zogenix’s 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the company’s board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix as an inducement to join the company. The awards consist of options to purchase an aggregate of 41,130 shares of Zogenix common stock and 21,040 restricted stock units. The options have a ten year term and an exercise price equal to $14.84 the closing price per share of the common stock on the grant date, and vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The restricted stock units vest over a four-year period in four equal annual installments beginning on the first anniversary of the vesting commencement date.]]>https://www.globenewswire.com/news-release/2021/11/11/2332944/0/en/Zogenix-to-Participate-in-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=55926Zogenix to Participate in Two Upcoming Investor Conferences2021-11-11T21:05:00Z<![CDATA[EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.]]>